BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 17927495)

  • 1. Lycopene and soy isoflavones in the treatment of prostate cancer.
    Vaishampayan U; Hussain M; Banerjee M; Seren S; Sarkar FH; Fontana J; Forman JD; Cher ML; Powell I; Pontes JE; Kucuk O
    Nutr Cancer; 2007; 59(1):1-7. PubMed ID: 17927495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soy isoflavones in the treatment of prostate cancer.
    Hussain M; Banerjee M; Sarkar FH; Djuric Z; Pollak MN; Doerge D; Fontana J; Chinni S; Davis J; Forman J; Wood DP; Kucuk O
    Nutr Cancer; 2003; 47(2):111-7. PubMed ID: 15087261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
    deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
    Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia.
    Fischer L; Mahoney C; Jeffcoat AR; Koch MA; Thomas BE; Valentine JL; Stinchcombe T; Boan J; Crowell JA; Zeisel SH
    Nutr Cancer; 2004; 48(2):160-70. PubMed ID: 15231450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk.
    Bunker CH; McDonald AC; Evans RW; de la Rosa N; Boumosleh JM; Patrick AL
    Nutr Cancer; 2007; 57(2):130-7. PubMed ID: 17571945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The specific role of isoflavones in reducing prostate cancer risk.
    Kumar NB; Cantor A; Allen K; Riccardi D; Besterman-Dahan K; Seigne J; Helal M; Salup R; Pow-Sang J
    Prostate; 2004 May; 59(2):141-7. PubMed ID: 15042614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen.
    Ide H; Tokiwa S; Sakamaki K; Nishio K; Isotani S; Muto S; Hama T; Masuda H; Horie S
    Prostate; 2010 Jul; 70(10):1127-33. PubMed ID: 20503397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial.
    Adams KF; Chen C; Newton KM; Potter JD; Lampe JW
    Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):644-8. PubMed ID: 15066931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum prostate-specific antigen but not testosterone levels decrease in a randomized soy intervention among men.
    Maskarinec G; Morimoto Y; Hebshi S; Sharma S; Franke AA; Stanczyk FZ
    Eur J Clin Nutr; 2006 Dec; 60(12):1423-9. PubMed ID: 16775579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer.
    Dalais FS; Meliala A; Wattanapenpaiboon N; Frydenberg M; Suter DA; Thomson WK; Wahlqvist ML
    Urology; 2004 Sep; 64(3):510-5. PubMed ID: 15351581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen.
    Grainger EM; Schwartz SJ; Wang S; Unlu NZ; Boileau TW; Ferketich AK; Monk JP; Gong MC; Bahnson RR; DeGroff VL; Clinton SK
    Nutr Cancer; 2008; 60(2):145-54. PubMed ID: 18444145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
    Ansari MS; Gupta NP
    Urol Oncol; 2004; 22(5):415-20. PubMed ID: 15464923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy.
    Clark PE; Hall MC; Borden LS; Miller AA; Hu JJ; Lee WR; Stindt D; D'Agostino R; Lovato J; Harmon M; Torti FM
    Urology; 2006 Jun; 67(6):1257-61. PubMed ID: 16765186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
    Schröder FH; Roobol MJ; Boevé ER; de Mutsert R; Zuijdgeest-van Leeuwen SD; Kersten I; Wildhagen MF; van Helvoort A
    Eur Urol; 2005 Dec; 48(6):922-30; discussion 930-1. PubMed ID: 16263208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men.
    Jenkins DJ; Kendall CW; D'Costa MA; Jackson CJ; Vidgen E; Singer W; Silverman JA; Koumbridis G; Honey J; Rao AV; Fleshner N; Klotz L
    J Urol; 2003 Feb; 169(2):507-11. PubMed ID: 12544298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.
    Pantuck AJ; Leppert JT; Zomorodian N; Aronson W; Hong J; Barnard RJ; Seeram N; Liker H; Wang H; Elashoff R; Heber D; Aviram M; Ignarro L; Belldegrun A
    Clin Cancer Res; 2006 Jul; 12(13):4018-26. PubMed ID: 16818701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones.
    Jarred RA; Keikha M; Dowling C; McPherson SJ; Clare AM; Husband AJ; Pedersen JS; Frydenberg M; Risbridger GP
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1689-96. PubMed ID: 12496063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.
    Moore MM; Stockler M; Lim R; Mok TS; Millward M; Boyer MJ
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):845-50. PubMed ID: 20082080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
    Lin AM; Rini BI; Weinberg V; Fong K; Ryan CJ; Rosenberg JE; Fong L; Small EJ
    BJU Int; 2006 Oct; 98(4):763-9. PubMed ID: 16796694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.